NUVB
The stock’s already done the moonwalk
Nuvation Bio has ripped more than 200%, which is usually the part where everyone starts talking like a genius in hindsight. But the new call is basically saying: yes, the launch story is getting better, but maybe pump the brakes before you start pricing in perfection.
Ibtrozi is doing the heavy lifting
The bright spot is Ibtrozi, which is now the leading ROS1 TKI in new patient starts. That’s not nothing — the drug posted $23.2 million in Q2 revenue and is seeing strong first-line uptake.
But there’s a catch, because there’s always a catch. Overall patient starts still declined sequentially, which tells you the launch isn’t exactly sprinting up the hill. Investors care because early commercial traction is nice, but durable demand is what turns a biotech from “interesting” into “worth the multiple.”
Big revenue dreams, smaller current reality
Management is talking up a $3.8 billion peak revenue opportunity for Ibtrozi. Analysts, meanwhile, seem to be squinting at the actual numbers and landing much closer to a ~$650 million trajectory.
That gap is the whole story here:
- Management sees blockbuster potential
- The market is asking for proof
- The stock has already done a lot of the proving for you
Big picture: this isn’t a collapse story — it’s a valuation reality-check story. When a stock has already rocketed, even a Hold can feel like a slap on the wrist.